FDA Approves First-in-Class Treatment for Myasthenia Gravis

TUESDAY, Dec. 21, 2021 -- Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food and Drug...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news